Use of IgG serology as a complement to diagnosis and severity biomarker in SARS-Cov-2 infection

CASTELLO A.A.; IGLESIAS G.; MANDILE M.G.; PERI IBAÑEZ E.S.; RAMIREZ C.; RAHHAL M.; SILVESTRE D.; ZUBIETA M.; ALLUISETTE M.; CURVALE C.; LAJE S.; BODEGA F.; ARGÜELLES M.H.; TEMPRANA C.F.; GLIKMANN G.

Michigan

Encuentro; ASV2021 40th Annual Meeting; 2021

American Society for Virology / University of Michigan Medical School

Determination of specific circulating IgG during and after a viral infection is useful in diagnosis, prevalence and vaccine studies. We determine SARS Cov-2 specific IgG titers at different time points along the course of the infection in order to look for confirmation of initial molecular diagnosis and putative correlations between titers and disease severity.Methods: 157 plasma samples from ambulatory asymptomatic or pauci-symptomatic patients attending and234 samples from severe patients admitted to intermediate and intensive care services were collected andstored at -80 ° C. The plasmas were analyzed by ELISA Covidar IgG (Lemos SA) qualitatively and selected samples were quantified obtaining their end point titer.Results:IgG is detectable in plasma from the first week of symptom onset in patients with different clinical presentations.The titres show significant differences (p